Iván Cabezas-Rodríguez

Iván Cabezas-Rodríguez

Auto-generated profile, based on publicly available information

Iván Cabezas-Rodríguez

Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in Rheumatology
Verified
Journal Article
Open access
PDF file
IRIoana Ruiz-Arruza
Ioana Ruiz-Arruza
AUAmaia Ugarte
Amaia Ugarte
ICIvan Cabezas-Rodriguez
Ivan Cabezas-Rodriguez
JMJose-Alejandro Medina
Jose-Alejandro Medina
MMMiguel-Angel Moran
Miguel-Angel Moran
GRGuillermo Ruiz-Irastorza
Guillermo Ruiz-Irastorza
Objective. The aim of this study was to analyse the relationship between glucocorticoids and damage accrual in SLE. Methods. We report an observational cohort study including 230 patients with SLE enrolled at diagnosis with 5 years of follow-up. Damage was calculated using the SLICC damage index. Glucocorticoid-related damage was defined as avascular osteonecrosis, osteoporotic fractures, diabetes mellitus or cataracts. Prednisone doses were calculated at the end of the fourth year of follow-up (prednisone-4). A categorical prednisone-4 variable was constructed: no prednisone, ≤7.5 mg/day (low dose), >7.5 mg/day (medium–high dose). The relationship between methylprednisolone pulses and damage was also tested. Results. By the fifth year, 188 patients (82%) had been treated with prednisone. Eighty-seven patients (37.8%) had accrued damage at 5 years. Patients with damage at year 5 had received a higher mean daily prednisone-4 dose (10.4 vs 6 mg/day, P < 0.001). The mean daily prednisone-4 dose was higher in patients accruing glucocorticoid-attributable damage (11 vs 7 mg/day, P = 0.04). Patients taking medium–high doses of prednisone-4 had a higher risk of accruing damage than those taking no prednisone [adjusted odds ratio (OR) 5.39, 95% CI 1.59, 18.27]. Patients taking medium–high doses of prednisone-4 were more likely to develop glucocorticoid-related damage than those on no prednisone (adjusted OR 9.9, 95% CI 1.1, 84). No differences were seen between patients on low doses and those on no prednisone. The cumulative dose of i.v. methylprednisolone-4 was not associated with global or glucocorticoid-related damage. Conclusion. Prednisone causes damage in SLE. Doses <7.5 mg/day and methylprednisolone pulses are not associated with damage accrual.

19 August 2015 in Rheumatology
Verified
Journal Article
Open access
PDF file
Rubén QueiroRubén Queiro
Rubén Queiro
IMIsla Morante
Isla Morante
ICIván Cabezas
Iván Cabezas
BABelén Acasuso
Belén Acasuso
Psoriasis and PsA are the main phenotypes of psoriatic disease. Both conditions are highly polygenic diseases in which stochastic and environmental factors are crucial in the pathogenic process. Although the MHC region is a highly dense genetic area, most of the genetic basis of psoriatic disease within it resides in the HLA region. For decades, HLA-C*06 has been accepted as the main descriptor of the two main phenotypes of skin psoriasis. There is now compelling evidence to suggest that HLA-C*06 is only a genetic biomarker for skin involvement and not for joint involvement in psoriatic disease. The role of HLA-B*27 in the genetic aetiology of PsA has been recognized since the 1970s. Recent population case–control studies with adequate patient groups and replication cohorts, as well as confirmation studies in family pedigrees through the use of modern molecular typing methods, have reinforced the aetiological role of this allele in PsA. These studies have offered a new vision of the role of this allele in disease expression. This review contextualizes the latest findings on the role of HLA-B27 in psoriatic disease, emphasizing those aspects of particular interest for clinical practice.

19 November 2012 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
JFJosé Fernández-Martín
José Fernández-Martín
JCJuan Jesus Carrero
Juan Jesus Carrero
MBMiha Benedik
Miha Benedik
WBWillem-Jan Bos
Willem-Jan Bos
ACAdrian Covic
Adrian Covic
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía
Chronic kidney disease–mineral and bone disorders (CKD–MBD) are important complications of CKD5D patients that are associated with mortality. COSMOS is a multicentre, open cohort, prospective, observational 3-year study carried out in haemodialysis patients from 20 European countries during 2005–07. The present article describes the main characteristics of the European dialysis population, the current practice for the prevention, diagnosis and treatment of secondary hyperparathyroidism and the differences across different European regions. The haemodialysis population in Europe is an aged population (mean age 64.8 ± 14.2 years) with a high prevalence of diabetes (29.5%) and cardiovascular disease (76.0%), and 28.7% of patients have been on haemodialysis more than 5 years. Patients from the former Eastern countries are younger (59.3 ± 14.3 versus 66.0 ± 13.9), having a lower proportion of diabetics (24.1 versus 30.7%). There were relevant differences in the frequency of measurement of the main CKD–MBD biochemical parameters [Ca, P and parathyroid hormone (PTH)] and the Eastern countries showed a poorer control of these biochemical parameters (K/DOQI and K/DIGO targets). Overall, 48.0% of the haemodialysis patients received active vitamin D treatment. Calcitriol use doubled that of alfacalcidiol in the Mediterranean countries, whereas the opposite was found in the non-Mediterranean countries. The criteria followed to perform parathyroidectomy were different across Europe. In the Mediterranean countries, the level of serum PTH considered to perform parathyroidectomy was higher than in non-Mediterranean countries; as a result, in the latter, more parathyroidectomies were performed in the year previous to inclusion to COSMOS. The COSMOS baseline results show important differences across Europe in the management of CKD–MBD.

1 October 2013 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
ICIván Cabezas-Rodriguez
Iván Cabezas-Rodriguez
JCJuan Jesús Carrero
Juan Jesús Carrero
carmine zoccalicarmine zoccali
carmine zoccali
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
MKMarkus Ketteler
Markus Ketteler
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía
Summary: Background and Objectives: A high body mass index (BMI) is associated with lower mortality in patients undergoing hemodialysis. Short-term weight gains and losses are also related to lower and higher mortality risk, respectively. The implications of weight gain or loss may, however, differ between obese individuals and their nonobese counterparts. Design, Setting, Participants, & Measurements: The Current Management of Secondary Hyperparathyroidism: A Multicenter Observational Study (COSMOS) is an observational study including 6797 European hemodialysis patients recruited between February 2005 and July 2007, with prospective data collection every 6 months for 3 years. Time-dependent Cox proportional hazard regressions assessed the effect of BMI and weight changes on mortality. Analyses were performed after patient stratification according to their starting BMI. Results: Among 6296 patients with complete data, 1643 died. At study entry, 42% of patients had a normal weight (BMI, 20–25 kg/m2), 11% were underweight, 31% were overweight, and 16% were obese (BMI ≥30 kg/m2). Weight loss or gain (1% of body weight) was strongly associated with higher rates of mortality or survival, respectively. After stratification by BMI categories, this was true in nonobese categories and especially in underweight patients. In obese patients, however, the association between weight loss and mortality was attenuated (hazard ratio, 1.28 [95% confidence interval (CI), 0.74 to 2.14]), and no survival benefit of gaining weight was seen (hazard ratio, 0.98 [95% CI, 0.59 to 1.62]). Conclusions: Assuming that these weight changes were unintentional, our study brings attention to rapid weight variations as a clinical sign of health monitoring in hemodialysis patients. In addition, a patient’s BMI modifies the strength of the association between weight changes with mortality.

1 January 2009 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
GPGiselle Pentón-Rol
Giselle Pentón-Rol
MCMajel Cervantes-Llanos
Majel Cervantes-Llanos
Gregorio Martínez-SánchezGregorio Martínez-Sánchez
Gregorio Martínez-Sánchez
JCJosé A Cabrera-Gómez
José A Cabrera-Gómez
CVCarmen M Valenzuela-Silva
Carmen M Valenzuela-Silva
PLPedro A López-Saura
Pedro A López-Saura
Neuromyelitis optica is a central nervous system demyelinating and inflammatory syndrome. The objective of this study is to identify cytokines related to the cellular immune response as well as blood brain barrier integrity and oxidative stress.

1 January 2013 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
AMAurora Menéndez
Aurora Menéndez
JGJesús Gómez
Jesús Gómez
LCLuis Caminal-Montero
Luis Caminal-Montero
JDJosé Bernardino Díaz-López
José Bernardino Díaz-López
ICIván Cabezas-Rodríguez
Iván Cabezas-Rodríguez
LMLourdes Mozo
Lourdes Mozo
Little information exists about the association of anti‐SSA/Ro60 and anti‐Ro52/TRIM21 with systemic lupus erytematosus (SLE) features. In this work, we analysed the associations of both anti‐Ro reactivities with clinical and immunological manifestations in 141 SLE patients. Photosensitivity and xerophtalmia/xerostomia were found to be positively associated with both anti‐SSA/Ro60 (P = 0.024 and P = 0.019, resp.) and anti‐Ro52/TRIM21 (P = 0.026 and P = 0.022, resp.). In contrast, a negative association was detected regarding anti‐phospholipid antibodies, anti‐SSA/Ro60 having a stronger effect (P = 0.014) than anti‐Ro52/TRIM21. Anti‐SSA/Ro60 showed a specific positive association with hypocomplementemia (P = 0.041), mainly with low C4 levels (P = 0.008), whereas anti‐Ro52/TRIM21 was found to be positively associated with Raynaud’s phenomenon (P = 0.026) and cytopenia (P = 0.048) and negatively associated with anti‐dsDNA (P = 0.013). Lymphocytes are involved in the relationship between anti‐Ro52/TRIM21 and cytopenia since positive patients showed lower cell levels than negative patients (P = 0.036). In conclusion, anti‐SSA/Ro60 and anti‐Ro52/TRIM21 showed both common and specific associations in SLE. These data thus increase evidence of the different associations of the two anti‐Ro specificities even in a particular disease.